• OPEN AN ACCOUNT
Indian Indices
Sensex
83,576.24 -604.72
( -0.72%)
Global Indices
Nasdaq
49,520.87 233.75
(0.47%)
Dow Jones
6,986.78 44.32
(0.64%)
Hang Seng
51,918.01 800.75
(1.57%)
Nikkei 225
10,123.15 78.46
(0.78%)
Forex
USD-INR
89.91 -0.02
(-0.02%)
EUR-INR
104.90 -0.20
(-0.19%)
GBP-INR
120.86 -0.43
(-0.35%)
JPY-INR
0.57 0.00
(-0.15%)

EQUITY - MARKET SCREENER

Union Bank of India
Industry :  Banks - Public Sector
BSE Code
ISIN Demat
Book Value()
532477
INE692A01016
151.6107853
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
UNIONBANK
6.9
123817.08
EPS(TTM)
Face Value()
Div & Yield %
23.52
10
2.93
 

Marksans Pharma gains after USFDA clears Goa facility with zero observations
Nov 10,2025
In a filing exchange filing, the company stated that the inspection was carried out at its second manufacturing facility, located at Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, India, from 3 November 2025 to 7 November 2025. The inspection concluded with zero Form 483 observations.

Mark Saldanha, managing director said, “The successful outcome of the cGMP inspection by the US FDA is a testament to our ongoing commitment to product quality and regulatory compliance.”

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit dropped 34.3% to Rs 58.31 crore despite of 4.97% jump in revenue from operations to Rs 619.98 crore in Q1 FY26 over Q1 FY25.